FDA approves Ingrezza to treat tardive dyskinesia
Ingrezza (valbenazine) has been approved by the Food and Drug Administration for the treatment of tardive dyskinesia in adults. Read More »
Ingrezza (valbenazine) has been approved by the Food and Drug Administration for the treatment of tardive dyskinesia in adults. Read More »
Amgen's results from its Phase 3 Tower study evaluating Blincyto’s efficacy have been published in the New England Journal of Medicine. Read More »
Tocagen Inc. recently announced that its Toca 511 & Toca FC drug received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Read More »
Genentech's Ocrevus, the only medicine capable of treating both relapsing and primary progressive forms of multiple sclerosis, has been approved by the U.S. Food and Drug Administration. Read More »
McKesson, the platinum sponsor of CBI’s Formulary, Co-Pay and Access Summit is presenting a new approach to patient-centric behavioral coaching with the overall goal of improving adherence despite affordability and other barriers. Read More »
Biologics Inc., which is owned by McKesson Specialty Health, has been chosen as the exclusive specialty pharmacy provider for BAVENCIO (avelumab). Read More »
Health care supply distributor McKesson Corp. of San Francisco has completed its acquisition of CoverMyMeds LLC, an Ohio-based source of electronic authorization technology for medical providers and pharmacists. Read More »
Change Healthcare recently announced the unveiling of InterQual 2017, the company’s flagship clinical decision support solution. Read More »
Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »
Amgen recently announced that the company submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for Xgeva (denosumab). The company also seeks approval from the European Medicines Agency (EMA). Read More »
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 11-0 on a favorable benefit-risk ratio for Genentech's rituximab/hyaluronidase subcutaneous injections in treating certain blood cancers. Read More »
Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »
Genentech's drug Rituxan was recently granted Breakthrough Therapy Designation Status by the U.S. Food and Drug Administration. Read More »
Based on 27,564 patient cardiovascular outcomes study, Amgen has established that maximally reducing low-density lipoprotein cholesterol levels with Repatha leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations. Read More »
Amgen recently announced that the European Commission (EC) granted the company authorization to bring to market Amgevita in all available indications. Read More »
Amgen's data from two studies shows that for appropriate patients in the United States, the majority of prescription claims for PCSK9 inhibitors, such as Repatha (evolocumab), were initially rejected. Read More »
Biologics Inc., an oncology pharmacy services company owned by McKesson Specialty Health, was selected by Novartis to be a specialty pharmacy provider for KISQALI (ribociclib). Read More »
Amgen recently announced the results of the Repatha (evolocumab) cognitive function trial that examined cognitive function for 1,974 patients enrolled in the Repatha cardiovascular outcomes study. Read More »
Amgen recently announced positive data from the Phase 3 '482 study, which is the largest international multiple myeloma trial ever conducted. Read More »
Amgen's positive results from a planned overall survival interim analysis of the Phase 3 head-to-head ENDEAVOR trial. Read More »